Loading…
for educational and safety purposes
Nicotine and Varenicline both come up in the same conversations; they overlap on Acetylcholine and Dopamine. Nicotine: nicotine is a genuinely nootropic nicotinic agonist with a small, real, meta-analysis-backed edge on attention and psychomotor speed (bigger in cholinergic-deficit brains than in healthy young ones), delivered through α4β2, α6 and α7 receptors; the honest catch is that it's an addictive drug whose habit-forming power scales with how fast you take it, so the entire case for using it rests on non-combusted low-dose delivery and clear eyes about dependence. Varenicline: varenicline (chantix/champix) is a cytisine-derived nicotinic partial agonist and a first-line smoking-cessation drug; a high-affinity partial agonist at alpha4beta2 (its core mechanism), full agonist at alpha7, partial at alpha3beta4, and only a weak partial agonist at the alpha6beta2* dopamine-terminal receptors that gate nicotine reward; effective for quitting, with nausea as the main trade-off.
nicotine is a genuinely nootropic nicotinic agonist with a small, real, meta-analysis-backed edge on attention and psychomotor speed (bigger in cholinergic-deficit brains than in healthy young ones), delivered through α4β2, α6 and α7 receptors; the honest catch is that it's an addictive drug whose habit-forming power scales with how fast you take it, so the entire case for using it rests on non-combusted low-dose delivery and clear eyes about dependence.
varenicline (chantix/champix) is a cytisine-derived nicotinic partial agonist and a first-line smoking-cessation drug; a high-affinity partial agonist at alpha4beta2 (its core mechanism), full agonist at alpha7, partial at alpha3beta4, and only a weak partial agonist at the alpha6beta2* dopamine-terminal receptors that gate nicotine reward; effective for quitting, with nausea as the main trade-off.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
agonist (high-affinity subtype)
indirect agonist via nAChR
functional desensitization then increased receptor number
agonist
agonist
agonist (low-affinity, rapidly desensitizing)
high-affinity partial agonist
partial agonist
full agonist
weak partial agonist
weak partial agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.